FR

We are #MobilisationTriplettes, a collective of daughters, wives, sisters, mothers, friends, relatives and patients affected by triple-negative breast cancer.
We are launching this petition to ensure access to TRODELVY in France and Europe as a whole.

Because thousands of young women have metastatic triple-negative breast cancer.
Because in France we have no access to the innovative treatments available elsewhere, metastatic patients still have an outdated protocol based on chemotherapy alone, until their dying breath.
Because an innovative treatment (TRODELVY) exists to double the life expectancy of these women diagnosed with this particularly aggressive breast cancer.
Because this treatment is available to in the U.S. but is not available in France or elsewhere in Europe.

Let's bring visibility to the need for accessibility to this life-giving treatment by signing this petition!

Despite numerous advances in research, some breast cancers remain difficult to treat. This is the case for one of the most aggressive known cancers: "triple-negative" breast cancer. This cancer strikes approximately 11,000 women a year, many of whom are young. 30% of patients will metastasize within 3 years of their diagnosis, representing 1,700 patients each year. Once the disease is metastatic, the median survival time in France is estimated at 14 months.

There is a treatment to nearly double the life expectancy of women with metastatic triple-negative breast cancer. This treatment is TRODELVY (Sacituzumab Govitecan), produced by the GILEAD Sciences laboratory.

TRODELVY is available in the United States. All American patients are given priority access to benefit from its ability to double the number of precious days left in a woman’s life.

In France:
- Compassionate access to TRODELVY as an investigational new drug was granted in mid-December 2020, pending final approval. This brought renewed hope for patients with metastatic triple-negative breast cancer.
- At the end of January, this access was suspended for any new request for TRODELVY. Only 50 patients were able to access it in the short time it was available.

This situation causes an injustice and a loss of opportunity for all patients who have reached the end of their therapeutic options.

THIS LACK OF ACCESS IS LINKED TO A PRODUCTION PROBLEM AT THE GILEAD LABORATORY.

It is not a European or French administrative problem.

Gilead has announced that the availability of Sacituzumab Govitecan (TRODELVY) in France will only be available starting in December 2021. Gilead makes no commitment to progressive availability before that time.

Waiting until the end of the year to benefit from Sacituzumab Govitecan (TRODELVY) is unacceptable for all patients who have arrived at the end of their therapeutic options.

It is impossible for us to remain inactive knowing that waiting will result in the death of these young women with metastatic triple-negative breast cancer and that their children will grow up without a mother.

THIS EMERGENCY IS A QUESTION OF LIFE OR DEATH!

Please help us by signing the petition to Gilead: ACCELERATE THE SUPPLY OF TRODELVY IN FRANCE (AND IN EUROPE). EXTENDING THE LIVES OF WOMEN CAN NOT WAIT UNTIL THE END OF THE YEAR.

TOGETHER, LET'S SAVE LIVES!

 
 
 #MobilisationTriplettes Collective - For more information, find us on our Twitter or Linkedin or  Facebook page or Instagram